KORU Medical partners for Phase III trial in rare kidney disorder
Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.
Koru Medical announces Phase 3 trial collaboration for new drug indication
Systems announced a collaboration with a global pharmaceutical manufacturer on a Phase III clinical trial for an expanded ...
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the ...